Aqilion divests its holding in Oncorena Holding AB

AQILION AB (publ) today announces that the company has divested its entire holding in Oncorena Holding AB. The decision is in line with Aqilion's strategy to focus the business to the internal pipeline programs within chronic inflammation. Aqilion has sold its holding to existing owners in Oncorena Holding AB.

“Aqilion was involved in starting Oncorena and has supported the company for a long time. It is positive for the company's continued development that the existing life science specialized investors have acquired our holding and continue to actively support Oncorena in their future development," says Sarah Fredriksson, CEO of Aqilion.

Oncorena is developing a new and potentially groundbreaking treatment for patients with advanced kidney cancer.

For further information, please contact:
Sarah Fredriksson, vd, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com
Gustaf Albèrt, CFO, AQILION AB, + 46 (0)709 168 302, gustaf.albert@aqilion.com

About Aqilion

Aqilion is a biotech company that focuses on developing innovative new treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases.

We identify innovative ideas that could potentially lead to new medications and refine them into commercially interesting projects. The innovation approach is based on solid scientific grounds, in disease areas where we, with reasonable assumptions, can understand the underlying biology, clinical relevance of the mechanism, potential patient benefit and the likelihood for finding a partner.

The company is mainly active in the early phases of drug discovery, from idea to proof-of-concept in clinical trials. Aqilion executes it’s development programs in a partly virtual organization in close collaboration with selected partners, with specific expertise in drug development.

AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. www.aqilion.com